MA-based ZWI Therapeutics, Inc. secures $10m in series A round funding. The appointment of pharmaceutical industry veterans Drs. Larry Miller and Ron Cohen as Independent Directors to the company’s Board of Directors, and Dr. Ed Mascioli as Chief Executive Officer and Board Director.
Read also – NYC-based Ansel Health Inc. Secures $20M in Funding
Dr. Shaoyi Jiang, the Robert Langer ’70 Family and Friends Professor at Cornell University, ZWI Board member, and co-founder said, “After closing our Series A $10 million financing from Co-win Ventures and Sherpa Healthcare Partners, engaging such high caliber executives in our company is a testimony to the confidence successful entrepreneurs see in the ZWI technology. Ed Mascioli’s significant experience leading multiple biotech companies is important in our Company’s growth”.
Dr. Mascioli. ZWI created new polymers said, “As board members, Ron and Larry collectively bring decades of successful pharmaceutical industry experience to ZWI. We will utilize their extensive expertise as ZWI advances its pipeline of wholly-owned and differentiated candidates that aim to tackle immunogenicity of protein therapeutics – a major challenge in biologics development”.
ZWI’s lead program, ZWI-001 (uricase-polycarboxybetaine conjugate), has demonstrated preclinical proof of concept and is currently in development to treat hyperuricemia in severe gout.
Read also – Chile-based Biotechnology Company PhageLab Secures $11M in Funding
About ZWI Therapeutics, Inc.
ZWI, founded in 2020 by Drs. Bob Langer and Shaoyi Jiang, is a biotechnology company using a novel, patented polymer, polycarboxybetaine, to develop protein-polymer conjugates with potentially superior safety and efficacy over currently marketed therapeutics conjugated with polyethylene glycol (PEG).
Read also – CA-based XGS Energy Secures $9.7M in Funding
